Scilex Holding Co
Company Profile
Business description
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Contact
960 San Antonio Road
Palo AltoCA94303
USAT: +1 650 516-4310
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
31
Stocks News & Analysis
stocks
What does big US court decision mean for Google’s parent company Alphabet?
stocks
Is this still an ASX share to own forever?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,140.50 | 11.00 | 0.12% |
CAC 40 | 7,674.78 | 24.14 | -0.31% |
DAX 40 | 23,596.98 | 173.35 | -0.73% |
Dow JONES (US) | 45,357.82 | 263.47 | -0.58% |
FTSE 100 | 9,208.21 | 8.66 | -0.09% |
HKSE | 25,417.98 | 359.47 | 1.43% |
NASDAQ | 21,661.67 | 46.03 | -0.21% |
Nikkei 225 | 43,018.75 | 438.48 | 1.03% |
NZX 50 Index | 13,223.53 | 90.33 | 0.69% |
S&P 500 | 6,470.21 | 31.87 | -0.49% |
S&P/ASX 200 | 8,871.20 | 8.60 | 0.10% |
SSE Composite Index | 3,812.51 | 46.64 | 1.24% |